Prognosis and prospect of metabolomics research of primary open-angle glaucoma

Authors: Xu Jianming,  Zhang Mingzhi
DOI: 10.3760/cma.j.cn115989-20220518-00224
Published 2023-12-10
Cite as Chin J Exp Ophthalmol, 2023, 41(12): 1221-1226.

Abstract                              [Download PDF] [Read Full Text]

Primary open-angle glaucoma (POAG) is an irreversible blinding eye disease that severely threatens and damages the optic nerve and visual pathways.Due to the diversity of causes and factors influencing its pathogenesis, the study of its pathogenesis has been a hot spot for research in this field.In recent years, metabolomics, as an emerging method, has been mainly applied in the prediction, diagnosis and prognosis assessment of ophthalmic diseases, providing characteristic metabolites with clinical guidance.Untargeted, targeted and widely targeted metabolomics methods based on nuclear magnetic resonance spectroscopy and mass spectrometry platforms have been applied to screen a large number of highly selective, sensitive and specific biometabolite products and biomarkers, and systems and technical platforms for metabolomics have been developed to track biological changes at all levels in POAG research, providing a foundation for further application of metabolomics in POAG clinical research in the future.This article reviews metabolomics and its clinical implications, advances in animal model-based metabolomics research, and advances in clinical metabolomics research in patients with POAG.

Key words:

Metabolomics; Primary open-angle glaucoma; Biomarkers

Contributor Information

Xu Jianming

Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong, Shantou 515051, China

Zhang Mingzhi

Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong, Shantou 515051, China

(Read 24 times, 1 visits today)